What You Should Know:
– Caris Life Sciences® (Caris), a pioneer in precision medicine and next-generation AI TechBio innovation, announced a transformative collaboration with Ontada®, a leading organization in oncology real-world evidence, clinical education, and point-of-care technologies.
– This partnership aims to advance cancer research, enhance healthcare delivery systems, and drive precision oncology through groundbreaking molecular research, data-driven solutions, and innovative therapies.
Advancing Precision Medicine: Caris Life Sciences and Ontada Collaborate to Revolutionize Oncology Research and Care
Strategic Pillars and Objectives
- The collaboration focuses on integrating Caris’ molecular-rich, multimodal database—comprising over 6.5 million tests and 13 quadrillion data points—with Ontada’s robust real-world oncology data, representing 2.4 million patient records across 80 tumor types.
- This combined resource enables life sciences companies to address complex questions in oncology research, paving the way for innovative treatment approaches.
- Key initiatives include developing multimodal data solutions, advancing research strategies, and delivering actionable cancer care intelligence.
Enhancing Oncology Care and Research
- By merging genomic data with real-world evidence, the partnership creates a unique platform to accelerate insights, conduct robust research, and streamline the pathway from discovery to clinical practice.
- These efforts aim to empower patients with faster access to personalized therapies, clinical trials, and informed treatment decisions, fostering innovation and improving outcomes in oncology care.
Commitment to Transformative Cancer Care
- “Rooted in rigorous science and patient-centered care, this collaboration represents a transformative approach to cancer research and treatment,” said David Spetzler, MS, PhD, MBA, President of Caris.
- By leveraging their respective strengths, Caris and Ontada bridge the gap between research and real-world application, offering life sciences companies unparalleled resources to revolutionize oncology.
Driving Innovation Through Synergy
- “The convergence of Caris’ sequencing power, AI-driven insights, and Ontada’s real-world oncology expertise delivers a differentiated platform for advancing precision medicine,” said Christine Davis, President of Ontada.
- This joint effort addresses the rapid evolution of oncology, fostering innovation, efficiency, and patient-centered outcomes in cancer care.
Revolutionizing Cancer Care Delivery
- The partnership also emphasizes collaborative research projects and clinical applications, aiming to improve cancer care across community settings, where 85% of cancer patients receive treatment, according to the National Cancer Institute.
- Dr. James Hamrick, Chairman of the Caris Precision Oncology Alliance™, highlighted the initiative’s potential to provide faster, more efficient access to personalized therapies, clinical trials, and data-driven treatment decisions.
This multi-faceted collaboration underscores a shared commitment to transforming cancer research and care through cutting-edge technology, precision medicine, and collaborative innovation.
